SLC5A2 and chronic kidney disease: Multiple studies including CREDENCE, DAPA-CKD, and EMPA-Kidney have demonstrated beneficial effects of SGLT2-inhibitors: lower risk of CKD progression, reduction of proteinuria, and lower risk of cardiovascular mortality.